Michael L. Lipton
<p><strong>Michael L. Lipton, M.D., Ph.D., F.A.C.R.</strong><br />Dr. Lipton, a neuroradiologist and neuroscientist, is Associate Director of the Gruss Magnetic Resonance Research Center at Einstein and Medical Director of MRI Services for Montefiore Health, both in New York. He divides his professional time between the clinical practice of neuroradiology, teaching and research. Dr. Lipton’s research broadly addresses the use of advanced noninvasive imaging technology to reveal heretofore-inaccessible substrates of brain dysfunction, particularly in the realms of behavior and cognition. More specifically, his research program has focused for nearly a decade on detecting and characterizing the effects of mild brain injury (AKA concussion). Specific areas of emphasis at present include the understanding of inter-individual differences in the manifestations of brain injury and the cumulative effects of repetitive subconcussive injury in sports. Dr. Lipton’s work on the impact of subconcussive “heading” on brain structure and function in amateur soccer players, funded by the Dana Foundation and the National Institutes of Health, has been reported extensively in the press worldwide.</p>
<p>Dr. Lipton develops and applies advanced quantitative MRI to enhance characterization of brain disease in patients with persistent symptoms related to traumatic brain injury and other disorders that are not adequately visualized using conventional imaging approaches</p>
<p>Dr. Lipton applies advanced imaging technology to characterize the effects of trauma on behavior and cognition. His work on repeated subconcussive head impacts in soccer players has been reported extensively in the press worldwide.</p>
<p>Michael L. Lipton, MD, PhD, FACR, is the Medical Director of MRI Services and an Attending Radiologist at Montefiore. He is also a Professor of Radiology, Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Lipton has been a member of the Montefiore team since 1997, with a clinical focus on developing advanced quantitative MRI to enhance characterization of brain diseases. He works primarily with patients who suffer persistent symptoms related to traumatic brain injury and other disorders that are not easily identified with conventional imaging approaches. </p><p>Dr. Lipton received his Doctor of Medicine from Boston University in 1990. He continued his studies by attending our Albert Einstein College of Medicine, where he received his Master of Science with Distinction and his Doctor of Philosophy in Neuroscience. His postgraduate training began with an internship in internal medicine at Brookdale Hospital Medical Center completed in 1991. Over 5 years, Dr. Lipton completed a residency and chief residency in diagnostic radiology, followed by a 2-year fellowship in neuroradiology at Montefiore, completing his postgraduate training in 1997. </p><p>Dr. Lipton has completed substantial research on repeated subconcussive head impacts in sports, particularly in soccer players. His work on this topic has been reported on extensively in the press worldwide. Dr. Lipton?s other research focuses mainly on the brain and has been shared in a number of presentations internationally, as well as published in numerous books and papers. </p><p>In 2017, Dr. Lipton received the Distinguished Investigator Award from the Academy of Radiology and Biomedical Imaging Research. Dr. Lipton is board certified by the American Board of Radiology, is a Fellow of the American College of Radiology and is a member of numerous professional societies, including the the American Medical Association, and the American Society of Neuroradiology. </p>
Mauricio Drummond, Jr.
Dr. Drummond’s clinical focus is in pediatric sports medicine with a special focus on knee pathology.
Dr. Drummond’s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears
<p>Mauricio Drummond Jr., MD, is an attending surgeon and Assistant Professor, Pediatrics and Orthopedic Surgery at Children’s Hospital at Montefiore. Dr. Drummond’s clinical focus is in pediatric sports medicine with a special focus on knee pathology. His interests include pediatric orthopedic surgery, complex pediatric and adolescent sports medicine, ACL, PCL and multiligament knee injuries, discoid meniscus, meniscus transplantation, patellofemoral instability, trochlear dysplasia, cartilage preservation and pediatric trauma and limb deformities.</p><p>In 1996, Dr. Drummond earned his Doctor of Medicine from Universidade Federal do Rio de Janeiro (Federal University of Rio de Janeiro) in Rio de Janeiro, Brazil. He completed his residency training at the same institution, and practiced as a knee specialist for more than 13 years in Brazil. In 2018, he came to the United States, completing an orthopedic surgery research fellowship at Cleveland Clinic Foundation in 2019 and an orthopedic sports medicine fellowship at the University of Pittsburgh Medical Center in 2020. He continued his postdoctoral training, completing his pediatric orthopedics and limb deformity fellowship at Montefiore Medical Center in 2021 and his pediatric orthopedics fellowship at Connecticut Children’s Medical Center in 2022.</p><p>Dr. Drummond’s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears. He has shared his work nationally and internationally through peer-reviewed journals and podium and poster presentations. He is also a reviewer for the <em>American Journal of Sports Medicine</em>.</p><p>Dr. Drummond is a member of several professional organizations including the International Society of Arthroscopy and Knee Orthopaedic Sports Medicine (ISAKOS), the American Orthopaedic Society for Sports Medicine (AOSSM), the Pediatric Orthopaedic Society of North America (POSNA) and the Pediatric Research in Sports Medicine Society (PRiSM).</p>
Shiu M. Young
Rui Yang
<p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopaedic residency at Peking University People’s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a Master’s degree in Biological Sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopaedic surgery residency at the University of Texas, in Houston and then he did a fellowship in Orthopaedic Oncology at Memorial Sloan-Kettering Cancer Center.</p>
<p>Dr. Yang specializes in the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system. A multidisciplinary approach is emphasized in his practice. He performs surgery to remove the tumor fom the limb and pelvis, and rebuild them using techniques tailored for each individual patient. Dr. Yang is also interested in treating metastatic bony lesions originating from other parts of the body.</p>
<p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumorigenesis of osteosarcoma and the genetic profile of the tumors as comparison to its normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, as well as novel strategies to overcome it in collaboration with the pediatric sarcoma teams.</p>
<p> </p>
Diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors.<quillbot-extension-portal></quillbot-extension-portal>
Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.<quillbot-extension-portal></quillbot-extension-portal>
<p>1. Peer-reviewed Papers</p>
<p>1) <strong>Yang, R.</strong>, Piperdi, S., Zhang, Y., Neophytou, N., Zhu, W., Hoang, B.H., Mason, G., Geller, D., Dorfman, H,, Healey, J.H., Phinney, D.G., and Gorlick, R. Transcriptional Profiling Identifies the Signaling Axes of the Insulin Growth Factor and the Transforming Growth Factor-beta as involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res. 2015. PMID: 26463566</p>
<p>2) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.,</strong> Linkov, I., Sowers, R., DiResta, G.R., Gorlick, R., Healey, J.H. Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma <a href="http://www.ncbi.nlm.nih.gov/pubmed/20052438">.</a> Ann Acad Med Singapore. 2009; 38(12):1041-7. PMID: 20052438</p>
<p>3) Li, N., <strong>Yang, R.</strong>, Zhang, W., Dorfman, H., Rao, P., and Gorlick, R. Genetically Transforming Human Mesenchymal Stem Cells to Sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer. 2009; 115(20): 4795-806. PMID: 19593798</p>
<p>4) <strong>Yang, R</strong>., Piperdi, S., and Gorlick, R. Activation of the RAF/MEK/ERK pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res. 2008;14(20): 6396-404. PMID: 18927278</p>
<p>5) <strong>Yang, R.</strong>, Qin, J., Hoang, B.H., Healey, J.H., and Gorlick, R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 2008;466:2046-51. PMID: 18528741</p>
<p>6) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.</strong>, Linkov, I., Sowers, R., Diresta, G.R., Gorlick, R., and Healey, J.H. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 2008;26:1-6. PMID: 18473395</p>
<p>7) <strong>Yang, R.</strong>, Li, W.W., Hoang, B.H., Kim, H., Banerjee, D., Kheradpour, A., Healey, J.H., Meyers, P.A., Bertino, J.R., and Gorlick, R. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008;8:124. PMID: 18452618</p>
<p>8) <strong>Yang, R.</strong>, Kolb, E.A., Qin, J., Chou, A., Sowers, R., Hoang, B., Healey, J.H., Huvos, A.G., Meyers, P.A. and Gorlick, R. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007;13:2557-67. PMID: 17473184</p>
<p>9) <strong>Yang, R.</strong>, Hoang, B.H., Kubo, T., Kawano, H., Chou, A., Sowers, R., Huvos, A.G., Meyers, P.A., Healey, J.H. and Gorlick, R. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007;121:943-54. PMID: 17410535</p>
<p>10) Laverdiere, C., Hoang, B.H., <strong>Yang, R.</strong>, Sowers, R., Qin, J., Meyers, P.A., Huvos, A.G., Healey, J.H. and Gorlick, R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-7. PMID: 15814634</p>
<p>11) Nathan, S.S., DiResta, G.R., Casas-Ganem, J.E., Hoang, B.H., Sowers, R., <strong>Yang, R.</strong>, Huvos, A.G., Gorlick, R. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005;11:2389-97. PMID: 15788690</p>
<p>12) Flintoff, W.F., Sadlish, H., Gorlick, R., <strong>Yang, R.</strong>, Williams, F.M. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 2004;1690:110-7. PMID: 15469899</p>
<p>13) Hoang, B.H., Kubo, T., Healey, J.H., <strong>Yang, R.</strong>, Nathan, S.S., Kolb, E.A., Mazza, B., Meyers, P.A. and Gorlick, R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64:2734-9. PMID: 15087387</p>
<p>14) Hoang, B.H., Kubo, T., Healey, J.H., Sowers, R., Mazza, B., <strong>Yang, R.</strong>, Huvos, A.G., Meyers, P.A. and Gorlick, R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106-11. PMID: 14735475</p>
<p>15) <strong>Yang, R.</strong>, Sowers, R., Mazza, B., Healey, J.H., Huvos, A., Grier, H., Bernstein, M., Beardsley, G.P., Krailo, M.D., Devidas, M., Bertino, J.R., Meyers, P.A. and Gorlick, R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003;9:837-44. PMID: 12576457</p>
<p> </p>
<p>2. Book Chapters</p>
<p align="left">1) Orthopedic Oncology. Editor: Xun, W.P., Feng, C.H. People’s Military Medical Publisher.</p>
<p>(ISBN: 7-80157-159-2), 2001.</p>
<p>2) Review of Surgery: A Guiding Book for Medical Students. Section of Orthopedics. Editor: Jiang, B.G. Beijing Medical University Publisher. (ISBN: 7-81034-946-5), 1999.</p>
<p>Dr. Yang is a fellowship-trained orthopedic surgeon recognized for his multidisciplinary approach to the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors. He also serves as an Assistant Professor at our Albert Einstein College of Medicine.</p><p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopedic residency at Peking University People?s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a master?s degree in biological sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopedic surgery residency at the University of Texas, in Houston, followed by a fellowship in orthopedic oncology at Memorial Sloan-Kettering Cancer Center.</p><p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.</p>
Mitchell C. Weiser
Treating conditions of the hip and knee, including osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, and osteonecrosis. <quillbot-extension-portal></quillbot-extension-portal>
Dr. Weiser's current research interests focus on post-operative pain management, surgical outcomes, infection, and airflow patterns in the operating room.<quillbot-extension-portal></quillbot-extension-portal>
<p>Mitchell Weiser, MD, is Director, Adult Reconstruction Joint Replacement Fellowship Program at Montefiore Einstein and Assistant Professor, Orthopedic Surgery at our Albert Einstein College of Medicine. He specializes in treating conditions of the hip and knee, including osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, and osteonecrosis. Dr. Weiser helps patients evaluate their surgical and non-surgical options, and helps them choose the most minimally invasive treatment whenever possible. When surgery is needed, he is skilled at performing both conventional and computer-navigated primary and revision (re-do) hip and knee replacements.</p><p>After completing two undergraduate engineering degrees from Rensselaer Polytechnic Institute, Dr. Weiser attended Cornell University, earning his Masters of Engineering. He earned his medical degree from the State University of New York at Stony Brook, and completed his residency in orthopedic surgery at the Icahn School of Medicine at Mount Sinai. He then completed an extra year of specialty fellowship training in joint replacement surgery at NYU Langone Medical Center and the Insall Scott Kelly Institute of Orthopedics and Sports Medicine.</p><p>Dr. Weiser’s research interests focus on post-operative pain management, surgical outcomes, infection and airflow patterns in the operating room. He has published numerous research articles in the <em>Journal of Bone and Joint Surgery, The Journal of Arthroplasty, Arthroplasty Today</em>, and the <em>Journal of American Association of Orthopedic Surgeons</em>. He has presented his research at national meetings including the annual meetings of the American Association of Orthopedic Surgeons, the Orthopedic Research Society, and the American Association of Hip and Knee Surgeons. He also serves as an academic journal reviewer for numerous medical journals including the <em>Journal of Arthroplasty, British Journal of Anaesthesia, Journal of Hip Surgery</em> and BMC Surgery.</p><p>Dr. Weiser is board certified, a Diplomate of the American Board of Orthopaedic Surgery and a member of the American Academy of Orthopedic Surgeons and the American Association of Hip and Knee Surgeons. He volunteers his time and expertise on a national level, serving as a committee member of the American Academy of Orthopedic Surgeons.</p>
Daniel A. Weiser
<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials. </p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children’s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. – Stony Brook University, NY</li>
<li>Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship – The Children’s Hospital of Philadelphia, PA</li>
</ul>
DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.
<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia. </p><p>Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>
Jacqueline Weingarten-Arams
Nutrition
Pulmonary hypertension
Sepsis
<p>Jacqueline Weingarten-Arams, MD, is an attending physician and Professor, Pediatrics at Montefiore Einstein. Dr. Weingarten-Arams’ pediatric critical care expertise focuses on cardiac critical care, acute hypoxemic respiratory failure, nutrition in critical illness and energy expenditure, cardiopulmonary resuscitation (quality CPR) and extracorporeal life support (ECMO).</p><p>After obtaining her Bachelor of Science in nutritional biochemistry at Cornell University in 1982, Dr. Weingarten-Arams earned her Doctor of Medicine at the same institution in 1986. She then completed her pediatric residency at Columbia University in 1990, where she was Chief Resident in her final year. Following this, Dr. Weingarten-Arams completed a fellowship in pediatric critical care medicine at New York Hospital Cornell University Medical College in 1996.</p><p>Dr. Weingarten-Arams research focus includes the use of deliberate simulated practice in improving outcomes in pediatric critical illness, pediatric resuscitation and pediatric airway management. Her other projects involve chronic critical illness, bioethics in pediatric critical care and oxidative injury in respiratory failure. She has been principal investigator and co-investigator on several research projects, and her work has been shared through numerous peer-reviewed publications and invited presentations.</p><p>Dr. Weingarten-Arams is a Diplomate of the National Board of Medical Examiners and the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and the American College of Chest Physicians. She is also a member of several professional organizations, including the American Medical Association, the Pediatric Cardiac Intensive Care Society and the Society of Critical Care Medicine. Dr. Weingarten-Arams has been named in Castle Connolly’s “Top Doctors: New York Metro Area” for multiple years. In 2006, she was inducted into the Leo M. Davidoff Society and in 2019, Dr. Weingarten-Arams won the William Obrinsky Award for Excellence in Medical Student Education.</p>
Dawn M. Wahezi
<p>Dr. Wahezi attended medical school at the University of Buffalo, School of Medicine and Biomedical Sciences. She completed her residency training in Pediatrics at The Children’s Hospital at Montefiore, where she stayed on as the inaugural fellow in Pediatric Rheumatology. She subsequently joined the faculty in the Department of Pediatrics at Montefiore and completed a Master’s Degree in clinical research through the Einstein-Montefiore Institute for Clinical and Translational Research Program. Dr. Wahezi is currently an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine and serves as the Program Director of the Pediatric Rheumatology Fellowship Program. </p>
<p>Dr. Wahezi has a special interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis. She has additionally established a pediatric Systemic Lupus Erythematosus (SLE) Cohort and participates in a dedicated, multi-disciplinary pediatric Lupus Nephritis Clinic. Dr. Wahezi is currently engaged in several research projects within the domains of JDM and SLE, contributing to over 40 peer reviewed manuscripts, reviews and scientific abstracts.</p>
<p>Dr. Wahezi is an active member of both the JDM subcommittee and SLE subcommittee within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and has participated in numerous observational and comparative effectiveness research protocols through this research consortium. </p>
<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Pediatric Rheumatology</span>
Dr. Wahezi has a particular research interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis.
<p></p>Dawn Wahezi, MD, MS, is Chief of the Division of Pediatric Rheumatology and Director of the Pediatric Rheumatology Fellowship Program at the Children’s Hospital at Montefiore. She is also Associate Professor of Pediatrics at our Albert Einstein College of Medicine.<br /><br />Dr. Wahezi received her Bachelor of Science from Loyola College and earned her Doctor of Medicine at the State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences. She obtained a Master of Science in Clinical Research at Albert Einstein College of Medicine, and did her residency and fellowship training at CHAM.<br /><br />Dr. Wahezi’s clinical and research interests include juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (SLE). At CHAM, she established an interdisciplinary clinic and comprehensive patient registry for children with JDM and SLE.. Dr. Wahezi is an active member of the American Academy of Pediatrics Rheumatology Advisory Board and the Childhood Arthritis and Rheumatology Research Alliance (CARRA).<p></p>
Pramod B. Voleti
Specializes in a wide variety of conditions involving the shoulder, elbow, and knee with a special interest and expertise in sports medicine, shoulder instability, rotator cuff tears, elbow tendinopathy, knee ligament reconstruction, meniscal pathology and cartilage restoration.<quillbot-extension-portal></quillbot-extension-portal>
Orthopedic Surgery<quillbot-extension-portal></quillbot-extension-portal>
<p>Pramod B. Voleti, MD, specializes in a wide variety of conditions involving the shoulder, elbow, and knee with a special interest and expertise in sports medicine, shoulder instability, rotator cuff tears, elbow tendinopathy, knee ligament reconstruction, meniscal pathology and cartilage restoration.</p><p>Dr. Voleti graduated from Princeton University with high honors. He then received his medical degree from SUNY Downstate College of Medicine. During medical school, he was elected to the Alpha Omega Alpha (AOA) Honor Society and earned the Christopher Pavlides Award for Excellence in Orthopedic Surgery. Dr. Voleti completed his orthopedics residency at the University of Pennsylvania, which included clinical rotations at the Hospital of the University of Pennsylvania, Pennsylvania Hospital, Penn Presbyterian Medical Center, Children?s Hospital of Philadelphia, and Philadelphia VA Medical Center, in addition to a one-year research fellowship in the renowned McKay Orthopedic Research Laboratory. He completed an additional fellowship training in sports medicine and shoulder surgery at the Hospital for Special Surgery. During this fellowship, he provided medical coverage for the Brooklyn Nets, Iona College Athletics, and high school football teams in the Public Schools Athletic League.</p><p>His research has been published in over 30 peer-reviewed publications, five book chapters, and thirty presentations at regional, national, and international meetings. He is a member of the American Academy of Orthopedic Surgery, the Arthroscopy Association of North America and the American Orthopedic Society for Sports Medicine.</p>